Atea Pharmaceuticals, Inc.

Atea reported cash and investments of about $220 million at June 30, 2026, versus $219.5 million cited elsewhere in the prepared remarks. In C-BEYOND, the primary modified intent-to-treat endpoint showed a 93.9% SVR rate for bemrusasvir versus 94.8% for sofosbuvir/velpatasvir at week 24, meeting the prespecified 5% non-inferiority margin. In the non-cirrhotic MITT population, SVR was 93.5% for bemrusasvir with 8 weeks of treatment versus 94.6% for sofosbuvir/velpatasvir with 12 weeks; in compensated cirrhosis, both arms achieved 95.4% SVR. Management said adverse events were comparable, with no serious adverse events due to study drug and no deaths in the bemrusasvir arm. For C-FORWARD, the company said the trial is fully enrolled with more than 880 patients and top-line results are expected in early Q1 2027; if positive, NDA submission is anticipated in Q2 2027. Management also reiterated that cash runway is expected to extend through 2027.

Jean-Pierre Sommadossi framed C-BEYOND as a significant milestone because it validated what he called a shorter, simpler path to cure for hepatitis C. He emphasized that the result came in a real-world, difficult-to-treat population and supports a best-in-class profile for a broad HCV market. His tone was upbeat and confident, and he tied the Phase 3 readout to upcoming regulatory work, a global data package, and eventual HCV eradication efforts.

Andrea Corcoran said cash and investments were $220 million at June 30, 2026, and that spending in the quarter was mainly directed to the HCV Phase 3 trials and, to a lesser extent, startup work for AT-587 in HEV. She said first-half 2026 R&D increased year over year due to higher external spend on the HCV Phase 3 program and HEV startup, partly offset by lower internal costs from reduced stock-based compensation and payroll-related costs. She also noted first-half G&A decreased year over year because of lower salaries, wages, and stock-based compensation, and reiterated that the company expects its cash runway to extend through 2027 while staying focused on HCV and HEV milestones.

Analysts focused on label strategy, test-and-treat adoption, guideline inclusion, the relevance of C-BEYOND’s non-inferiority data to C-FORWARD, and the impact of pricing reforms such as Medicare Part D, 340B, and reference pricing. Management said it is too early to discuss how the new mechanism of action will appear in the label, but plans to share the full dataset with the FDA early next year and present more data at scientific meetings. On test-and-treat, management said physicians want immediate treatment at diagnosis and that the blister packs are meant to support adherence, but payer and refill mechanics still need to be worked out. On C-FORWARD, management said ex-U.S. genotype mix will differ and patients may be more adherent, and on pricing reforms it said the impact may be less dramatic than some fear, with 340B changes potentially favorable if they move to a rebate model.